Sachin Kapur, MD
Neurology · Orland Park, ILNPI 1003064833
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $164,019 of the $214,035 with a category attached, or 76.6%. 29 manufacturers reported payments, led by MDD US Operations, LLC at 27.7% of the total. Reporting peaked in 2019 at $63,204 and has fallen 70.2% since, to $18,845 in 2025. Among neurology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 681 payments — averaging $314.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$59K
- Acadia Pharmaceuticals Inc$37K
- Acorda Therapeutics, Inc$32K
- Kyowa Kirin, Inc.$28K
- Neurocrine Biosciences, Inc.$24K
- Amneal Pharmaceuticals LLC$20K
- plus $13K from 23 others
What the payments were for
- Consulting fees$23,74911%
- Speaking & faculty fees$164,01977%
- Travel & lodging$11,0945%
- Food & beverage$12,7166%
- Education$2,4571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 80 | $59,373 |
| Acadia Pharmaceuticals Inc | 79 | $37,367 |
| Acorda Therapeutics, Inc | 55 | $32,474 |
| Kyowa Kirin, Inc. | 52 | $27,878 |
| Neurocrine Biosciences, Inc. | 40 | $24,010 |
| Amneal Pharmaceuticals LLC | 47 | $19,769 |
| Teva Pharmaceuticals USA, Inc. | 32 | $5,238 |
| AbbVie(2 entities) | 112 | $2,227 |
| Abbott | 40 | $1,957 |
| Boston Scientific | 7 | $1,197 |
| Sunovion Pharmaceuticals Inc. | 22 | $497 |
| Lundbeck LLC | 20 | $371 |
| Supernus Pharmaceuticals, Inc. | 22 | $285 |
| Adamas Pharmaceuticals, Inc. | 18 | $265 |
| Avion Pharmaceuticals | 12 | $213 |
| Merz Pharmaceuticals, LLC | 9 | $209 |
| Ipsen Biopharmaceuticals, Inc | 9 | $185 |
| SK Life Science, Inc. | 1 | $100 |
| UCB, Inc. | 4 | $97 |
| Pfizer | 4 | $75 |
| Arbor Pharmaceuticals, Inc. | 3 | $52 |
| Vertical Pharmaceuticals, LLC | 4 | $50 |
| Merz North America, Inc. | 2 | $32 |
| Avanir Pharmaceuticals, Inc. | 2 | $27 |
| Medtronic | 1 | $22 |
| Saol Therapeutics Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$214,035 in reported general payments places this provider in the 95th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 172 | $193,978 |
| GocovriAmantadine Hcl | 53 | $149,441 |
| NuplazidPimavanserin Tartrate | 26 | $125,608 |
| IngrezzaValbenazine Tosylate | 12 | $100,343 |
| NourianzIstradefylline | 32 | $83,860 |
| XadagoSafinamide Mesylate | 16 | $20,704 |
| NeuproRotigotine | 13 | $18,281 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 577 | $17,665 |
| Emgality PenGalcanezumab-Gnlm | 20 | $14,038 |
| Pyridostigmine Bromide | 43 | $8,349 |
| Ropinirole ErRopinirole Hcl | 66 | $8,157 |
| AmantadineAmantadine Hcl | 215 | $7,989 |
| Droxidopa | 38 | $7,970 |
| Propranolol Hcl ErPropranolol Hcl | 109 | $3,235 |
| Pramipexole ErPramipexole Di-Hcl | 18 | $3,023 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $19,769 | $202,327215 claims |
| MDD US Operations, LLCGocovri | $59,373 | $149,44153 claims |
| Acadia Pharmaceuticals IncNuplazid | $37,367 | $125,60826 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $24,010 | $100,34312 claims |
| Kyowa Kirin, Inc.Nourianz | $27,878 | $83,86032 claims |
| UCB, Inc.Neupro | $97 | $18,28113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 neurology providers in Illinois.
Other neurology in Orland Park
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Daniel WynnNorthbrook$812K
- Arthur ItkinPalos Heights$808K
- Andrew GordonLake Barrington$765K
- Martha McGrawWinfield$625K
- Reuben ValenzuelaPeoria$590K
- Adil JavedChicago$584K
- Tyler KaplanMaywood$549K
- Danny BegaChicago$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.